Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

By Anne L. Taylor, S. Ziesche, C. Yancy, P. Carson, Ralph B. D’Agostino, K. Ferdinand, Malcolm P. Taylor, K. Adams, M. Sabolinski, M. Worcel and 1 more. New England Journal of Medicine, 2004

1,650 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Emergency Medicine

View Paper: https://www.semanticscholar.org/paper/112e66031cb5676eeb3ae0cdc3a0bc4379a52a30

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. J. Cleland
3. W. Paulus
4. Gerasimos Filippatos
5. J. Januzzi
6. T. Horwich
7. L. Tavazzi
8. Jeroen J. Bax

In Emergency Medicine

1. Jeroen J. Bax

Citations in the corpus

• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, neutral): “ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ARNI ¼ angiotensin receptor neprilysin inhibitor; BNP ¼ B-type natriuretic peptide; CRT ¼ cardiac resynchronization therapy; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; H-ISDN ¼ hydralaz”
• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated (179,180).”
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “In a subsequent trial, which was limited to patients self-described as African American, the addition of a fixed-dose combination of hydralazine and isosorbide dinitrate to standard therapy with an ACE inhibitor or ARB, a beta blocker, and an aldosterone antagonist offered significant benefit (424).”
• A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. (2013, positive): “Long-term use of isosorbide dinitrate combined with the antioxidant hydralazine improved the outcome of HFREF patients in V-HEFT I (Vasodilator-Heart Failure Trials) and A-HEFT (African-American Heart Failure Trial) (87,88).”
• Oxygen, oxidative stress, hypoxia, and heart failure. (2005, neutral): “In that trial, combined therapy with hydralazine, a vasodilator that inhibits generation of O2•–, and isosorbide dinitrate improved quality-oflife scores and decreased mortality by approximately 45% in African Americans with severe heart failure (97).”